Sirolimus for epithelioid hemangioendothelioma (EHE)
Treatments studied
Part of Cancer clinical trials.
This trial tests a new form of sirolimus (a targeted therapy) for people with a rare cancer called EHE that is growing or causing symptoms. If you have EHE that can't be removed with surgery and needs treatment, this study may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been diagnosed with EHE that is progressing or causing symptoms and can't be surgically removed.
- You have at least one tumor that can be measured on scans.
- You are able to care for yourself (ECOG score 0–2) and have a life expectancy of more than 3 months.
- Your blood counts, kidney and liver function, cholesterol, triglycerides, and blood sugar are within certain limits.
- You haven't had certain cancer treatments (including mTOR inhibitors) in the last 2–6 weeks, and you don't have major uncontrolled medical issues like heart disease or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from European hospitals on people with epithelioid hemangioendothelioma (EHE), a rare tumor that grows in blood vessels. Joining this registry helps doctors learn more about the disease and improve care for others.
This trial studies sirolimus in adults with “warm” autoimmune hemolytic anemia (or Evans syndrome) when steroids have not worked or the anemia has returned. It may help control the immune attack on red blood cells, but there are specific safety checks for liver health and infections.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial tests if sirolimus (an immune-suppressing drug) works better than current treatments for aplastic anemia patients who did not improve or had side effects from cyclosporin. It aims to find a new option to help your body make more blood cells.
This trial is studying a drug called nab-sirolimus for people with a rare type of vascular tumor called epithelioid hemangioendothelioma (EHE) that is growing or causing symptoms. The goal is to see if the drug can help control the tumor.
This trial studies how the medicine sirolimus affects children’s response to routine vaccines during treatment for kaposiform hemangioendothelioma (KHE). It compares vaccinated KHE patients taking sirolimus with healthy children getting the same vaccines.
Hear when a new Epithelioid Hemangioendothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.